Processing math: 100%
ISSN 1004-4140
CN 11-3017/P
DOU P P, ZHAO H L, CAO A H. Spectral CT Combined with Tumor Markers to Predict Ki-67 Expression in Lung Adenocarcinoma[J]. CT Theory and Applications, 2023, 32(6): 753-760. DOI: 10.15953/j.ctta.2022.172. (in Chinese).
Citation: DOU P P, ZHAO H L, CAO A H. Spectral CT Combined with Tumor Markers to Predict Ki-67 Expression in Lung Adenocarcinoma[J]. CT Theory and Applications, 2023, 32(6): 753-760. DOI: 10.15953/j.ctta.2022.172. (in Chinese).

Spectral CT Combined with Tumor Markers to Predict Ki-67 Expression in Lung Adenocarcinoma

More Information
  • Received Date: August 24, 2022
  • Revised Date: January 14, 2023
  • Accepted Date: January 15, 2023
  • Available Online: February 26, 2023
  • Purpose: To investigate the predictive value of energy spectrum CT quantitative parameters combined with serum tumor markers (CEA, CA-125) on Ki-67 expression in lung adenocarcinoma. Methods: The clinicopathological and imaging data of 64 patients with lung adenocarcinoma confirmed by pathology from June 2020 to February 2022 were retrospectively analyzed. All patients underwent dual-phase energy spectrum CT examination, and serum CEA and CA-125 levels before treatment were clear. Based on postoperative pathological results, patients were divided into two groups, the high expression group of Ki-67 (>30%) and the low expression group of Ki-67 (≤30%). The iodine value (IC), standardized iodine ratio (NIC), and the slope of the energy spectrum curve (λHU) were measured by a dual-energy post-processing workstation. The expression levels of SERUM CEA and CA-125 before treatment were obtained according to medical records. Statistical analysis of the data was performed with SPSS 22.0; t-test or Mann−Whitney U test and χ2 tests were used to compare the differences in parameters between the two groups, and the ROC (receiver operating characteristic curve, ROC) curve was used to evaluate the prediction efficiency of the parameters. Results: The IC, NIC, and λHU values in the low expression group were higher than those of the high expression group, and the differences were statistically significant. Serum CEA and CA-125 levels in the Ki-67 high expression group were higher than those of the low expression group, and the difference was statistically significant. There were no significant differences in other parameters between the two groups. ROC curve analysis showed that CEA had the best predictive efficiency for Ki-67, with an area under the curve of 0.697, sensitivity of 39.17%, and specificity of 100%. Conclusions: The quantitative parameters of energy spectrum CT in the venous phase, serum CEA, and CA12-5 levels have a certain value in predicting the expression of Ki-67, which can provide a basis for selecting a clinical treatment plan.

  • [1]
    TRAVIS W D, BRAMBILLA E, NOGUCHI M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International multidisciplinary classification of lung adenocarcinoma[J]. Journal of Thoracic Oncology, 2011, 6(2): 244−285. doi: 10.1097/JTO.0b013e318206a221
    [2]
    ZHANG J, WU J, TAN Q, et al. Why do pathological stage IA lung adenocarcinomas vary from prognosis? A clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification[J]. Journal of Thoracic Oncology, 2013, 8(9): 1196−1202. doi: 10.1097/JTO.0b013e31829f09a7
    [3]
    陈海瑞, 李文才, 陈天东, 等. 原发性肺腺癌组织亚型及预后[J]. 河南医学研究, 2017,26(18): 3271−3273. doi: 10.3969/j.issn.1004-437X.2017.18.003

    CHEN H R, LI W C, CHEN T D, et al. Subtypes and prognosis of primary lung adenocarcinoma[J]. Henan Medical Research, 2017, 26(18): 3271−3273. (in Chinese). doi: 10.3969/j.issn.1004-437X.2017.18.003
    [4]
    WARTH A, MULEY T, MEISTER M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival[J]. Journal of Clinical Oncology, 2012, 30(13): 1438−1446. doi: 10.1200/JCO.2011.37.2185
    [5]
    ROSS D T, SCHERF U, EISEN M B, et al. Systematic variation in gene expression patterns in human cancer cell lines[J]. Nature Genetics, 2000, 24(3): 227. doi: 10.1038/73432
    [6]
    MARTIN B, PAESMANS M, MASCAUX C, et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis[J]. British Journal of Cancer, 2004, 91(12): 2018−2025. doi: 10.1038/sj.bjc.6602233
    [7]
    ISHIBASHI N, MAEBAYASHI T, AIZAWA T, et al. Correlation between the Ki-67 proliferation index and response to radiation therapy in small cell lung cancer[J]. Radiation Oncology, 2017, 12(16): 3−7.
    [8]
    LI Y, PAN Y, WANG R, et al. ALK-rearranged lung cancer in Chinese: A comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR[J]. Plos One, 2013, 8(7): e69016. doi: 10.1371/journal.pone.0069016
    [9]
    TOMIYAMA N, YASUHARA Y, NAKAJIMA Y, et al. CT-guided needle biopsy of lung lesions: A survey of severe complication based on 9783 biopsies in Japan[J]. European Journal of Radiology, 2006, 59(1): 60−64. doi: 10.1016/j.ejrad.2006.02.001
    [10]
    SHAN L, LIAN F, GUO L, et al. Detection of ROS1 gene rearrangement in lung adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR[J]. Plos One, 2015, 10(3): e0120422. doi: 10.1371/journal.pone.0120422
    [11]
    THIEME S F, GRAUTE V, NIKOLAOU K, et al. Dual energy CT lung perfusion imaging: Correlation with SPECT/CT[J]. European Journal of Radiology, 2012, 81(2): 360−365. doi: 10.1016/j.ejrad.2010.11.037
    [12]
    MCCOLLOUGH C H, LENG S, YU L, et al. Dual- and multi-energy CT: Principles, technical approaches, and clinical applications[J]. Radiology, 2015, 276(3): 637−653. doi: 10.1148/radiol.2015142631
    [13]
    LI G J, GAO J, WANG G L, et al. Correlation between vascular endothelial growth factor and quantitative dual-energy spectral CT in non-small-cell lung cancer[J]. Clinical Radiology, 2016, 71(4): 363−368. doi: 10.1016/j.crad.2015.12.013
    [14]
    KARCAALTINCABA M, AKTAS A. Dual-energy CT revisited with multidetector CT: Review of principles and clinical applications[J]. Diagnostic and Interventional Radiology, 2011, 17(3): 181−194.
    [15]
    de CECCO C N, DARNELL A, RENGO M, et al. Dual-energy CT: Oncologic applications[J]. American Journal of Roentgenology, 2012, 199(l): 98−105.
    [16]
    FORNARO J, LESCHKA S, HIBBELN D, et al. Dual- and multi-energy CT: Approach to functional imaging[J]. Insights Imaging, 2011, 2(2): 149e59.
    [17]
    LIN L Y, ZHANG Y, SUO S T, et al. Correlation between dual-energy spectral CT imaging parameters and pathological grades of non-small cell lung cancer[J]. Clinical Radiology, 2018, 73(4): 412.e1−412.e7. doi: 10.1016/j.crad.2017.11.004
    [18]
    YANG F, DONG J, WANG X, et al. Non-small cell lung cancer: Spectral computed tomography quantitative parameters for preoperative diagnosis of metastatic lymph nodes[J]. European Journal of Radiology, 2017, 89: 129−135.
    [19]
    SALGIA R, HARPOLE D, HERNDON J A, et al. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer[J]. Anticancer Research, 2001, 21(2B): 1241−1246.
  • Cited by

    Periodical cited type(0)

    Other cited types(2)

Catalog

    Article views (250) PDF downloads (21) Cited by(2)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return